Page 421 - Read Online

Page 9 of 36 J Cancer Metastasis Treat 2019;5:31 I http://dx.doi.org/10.20517/2394-4722.2019.21
3 Institut Pasteur Korea, Gyeonggi-Do 464-400, South Korea.
4 Celemics, Inc., Geumcheon-gu, Seoul 08506, South Korea.
5 Samsung Biologics, Incheon 21987, South Korea.
6 GSK Vaccines Research & Development, Rockville MD 20850, USA.

Next-generation sequencing (NGS) has allowed a massive increase in capacity to sequence genomes at
relatively low cost and in a short time frame. It has revolutionized multiple aspects of biological research
and is actively being adopted into profiling human B cell receptor (BCR) repertoires. Several NGS
platforms are currently available, with average read lengths of 75 bp to 8,500 bp and different error rates.

Using NGS, we successfully constructed database of human BCR repertoire from convalescent patients who
recovered from severe fever with thrombocytopenia and middle east respiratory syndrome. Afterwards,
we developed algorithms for analyzing the diversity, enrichment pattern, accumulation of somatic
hyper-mutation in BCR repertoire. Through in silico analysis we selected clones of interest and prepared
recombinant antibodies using a mammalian transient expression system. Their reactivity to viral coat
proteins and virus-neutralizing capability was confirmed in in vitro and in vivo experiments.

Currently we are investigating the clinical value of BCR repertoire profiling in autoimmune disease patients
including Neuromyelitis Optica and various cancers.

Biography
Junho Chung has completed his MD, PhD from Seoul National Univ. College of Medicine, South Korea. He
is the professor of Seoul National Univ., in the Department for Biochemistry and Molecular Biology. He has
published more than 95 papers in reputed journals and has been serving as a vice-editor-in chief of Journal
of Cancer Research and Clinical Oncology.

12. Biobank in Pilsen, Czech Republic, efficient tool for cancer research and personalised
treatment

Judita Kinkorová, Ondřej Topolčan

Department of Immunochemistry, University Hospital Pilsen, Pilsen 304 60, Czech Republic.

Biobank in University Hospital (UH) Pilsen is newly established (opened in April 2017) hospital integrated
biobank, based on previous high quality sample collection. Sinece 2000 the hospital respository started
to collect and store systematically biological material of patiens for research in the UH. The main
diagnoses for sample collection are oncological samples of breast cancer, colorectal cancer, liver and kidney
carcinoma, and prostate cancer.

To be a fully-fledged biobank the following activites have been realised: collection and storage high
quilty biological material (blood, serum and plasma) of oncological patients, collection management and
storage of related data, implementation of ethical, social and legal issues, harmonization of IT systems,
implementation of relevant requrements for providing biological material to the Czech Republic and
abroad, preparation of education and training programmes and courses, active participation on BBMRI -
ERIC activities, and cross-boarder collaboration in the BRoTHER projet.

Currently is the biobank ready to implement aspects of personalised medicine in practice. Regarding the
high quality aspects the selected long and short term stability of tumor markers are studied. Together